Drug Profile


Alternative Names: ALX-0600; Gattex; Revestive

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Toronto General Hospital; University of Toronto
  • Developer Shire; Takeda Pharmaceuticals International GmbH
  • Class Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease

Highest Development Phases

  • Marketed Short bowel syndrome
  • Suspended Crohn's disease
  • No development reported Mucositis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Mucositis(Chemotherapy-induced) in USA (SC, Injection)
  • 16 Aug 2017 Shrine initiates enrolment in a phase III trial for Short bowel syndrome (In adults, In adolescents, In children) in Japan (NCT03268811)
  • 19 May 2017 Registered for Short bowel syndrome (In adults) in Australia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top